HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The impact of allodynia on the efficacy of almotriptan when given early in migraine: data from the "Act when mild" study.

Abstract
The objective of this study was to evaluate the impact of allodynia on treatment outcomes in the patients with acute migraine treated in the "Act when Mild" (AwM) study. AwM, a randomized placebo-controlled trial, studied almotriptan 12.5 mg in the early treatment (within 1 hr) of acute migraine when the pain was still mild, and investigated clinical outcomes in the presence or absence of allodynia, which was prospectively recorded using patient questionnaires. Of the total population, 39% (n = 404) reported allodynia that did not alter the efficacy of almotriptan administered for early/mild pain in terms of 2-hr pain-free rates (53.9% for allodynic patients vs. 52.5% for nonallodynic patients). Similarly, sustained pain-free rates were 47.2% versus 45.5%, and migraine duration 1.40 versus 1.54 hr, respectively. However, allodynia impaired the effectiveness of almotriptan in the patients with moderate/severe pain in terms of longer migraine duration, fewer patients achieving pain-free status, and more requiring rescue medication. In conclusion, the lack of effect of allodynia on the efficacy of almotriptan given for early/mild migraine pain might help explain the improved outcomes associated with the early-treatment strategy in AwM. Moreover, the data suggest that pain intensity is the main driver of triptan response, and not the presence or absence of allodynia.
AuthorsS Díaz-Insa, P J Goadsby, G Zanchin, J Fortea, M Falqués, C Vila
JournalThe International journal of neuroscience (Int J Neurosci) Vol. 121 Issue 12 Pg. 655-61 (Dec 2011) ISSN: 1563-5279 [Electronic] England
PMID21777163 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Tryptamines
  • almotriptan
Topics
  • Adult
  • Double-Blind Method
  • Female
  • Humans
  • Hyperalgesia (drug therapy, epidemiology, physiopathology)
  • Male
  • Migraine Disorders (drug therapy, epidemiology, physiopathology)
  • Pain (drug therapy, epidemiology)
  • Pain Measurement (drug effects, methods)
  • Prospective Studies
  • Time Factors
  • Treatment Outcome
  • Tryptamines (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: